CDSCO Panel Reviews Novo Nordisk’s PMS Study, Clears Data on Oral Semaglutide We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Novo Nordisk’s strategy in India is shaped not by competitive pressures but by a long-term commitment to the country, Vikrant Shrotriya, the India head of the Danish drugmaker, told ET. “We are not in a numbers game. What is more satisfying is when you see people benefiting from the medicine… And when we do this…
CDSCO Panel seeks clarifications from Novo Nordisk on IcoSema phase IIIb clinical study protocol We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
CDSCO Panel Approves New Indications for Novo Nordisk’s Semaglutide, Mandates PMS Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link